Christina DiLauro Abaya
Papers
1
Total Citations
2
H-Index
1
About
Dr. Christina DiLauro Abaya is a pioneering oncologist whose research focuses on harnessing the immune system to combat triple-negative breast cancer (TNBC), one of the most aggressive and treatment-resistant subtypes. Her most cited work, a 2019 paper, introduces a novel randomized phase II trial combining peri-operative immunotherapy (ipilimumab and nivolumab) with cryoablation—a technique that freezes tumors to trigger immune responses—in women with residual early-stage TNBC after standard neoadjuvant chemotherapy. This study, with 2 citations, represents a critical step toward personalized, immune-based strategies for high-risk patients. Dr. Abaya’s contributions lie at the intersection of immunotherapy and local ablation, aiming to convert "cold" tumors into "hot" ones to improve outcomes. Her work underscores a shift from conventional cytotoxic therapies to targeted immunomodulation, potentially reducing recurrence and enhancing survival. While her citation count is modest, the innovative design of her trial—integrating checkpoint inhibitors with cryoablation—positions her as a rising voice in translational oncology. For students and researchers, Dr. Abaya exemplifies how early-career investigators can tackle pressing clinical challenges with creative, multidisciplinary approaches that bridge laboratory insights and patient care.
Research Focus
Key Achievements
Top Papers
- 1